StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

Equities researchers at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 3.1 %

Evoke Pharma stock opened at $2.79 on Friday. Evoke Pharma has a 52 week low of $2.50 and a 52 week high of $12.32. The stock has a market cap of $4.17 million, a price-to-earnings ratio of -0.25 and a beta of 0.12. The company’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $4.64.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%. The company had revenue of $3.31 million for the quarter, compared to analyst estimates of $3.08 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC increased its position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the period. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.